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oRIGINAL ARTICLE
Introduction: Belotecan (Camtobell, CKD602) is a new camp-
tothecin-derivative antitumor agent that belongs to the topoi-
somerase inhibitors. The aim of this study was to evaluate the 
efficacy and safety of belotecan monotherapy as a second-line 
therapy in patients with relapsed or refractory small cell lung can-
cer (SCLC).
Methods: Between June 2008 and August 2011, a total of 50 patients 
with relapsed or refractory SCLC were treated with belotecan 0.5mg/
m2 for 5 consecutive days, every 3 weeks. We evaluated the overall 
response rate (oRR), the progression-free survival (PFS), and the 
overall survival (oS), and toxicity according to sensitivity to initial 
chemotherapy.
Results: The median age was 66 years (range, 43–84 years) and 
Eastern Cooperative oncology Group performance was 0 or 1 in 34 
patients (68%) and 2 in 16 patients (32%). Twenty patients (40%) 
had sensitive relapse and 30 patients (60%) had refractory disease. 
The oRR, PFS, and oS for sensitive patients were 20% (95% confi-
dence interval [CI], 8–40), 2.8 months (95% CI, 0.53–5.06), and 6.5 
months (95% CI, 1.58–11.42), respectively. In the refractory group, 
the oRR, PFS, and oS were 10% (95% CI, 1–21), 1.5 months (95% 
CI, 1.25–1.75), and 4.0 months (95% CI, 3.40–4.60), respectively. 
Most commonly reported grade-3 or -4 adverse events included neu-
tropenia (54%), thrombocytopenia (38%), and anemia (32%).
Conclusion: Belotecan showed modest activity with an acceptable 
safety profile as a second-line therapy in patients with relapsed or 
refractory SCLC.
Key Words: Belotecan, Relapsed, Refractory, Small cell lung 
cancer.
(J Thorac Oncol. 2012;7: 731–736)
Small cell lung cancer (SCLC) comprises approximately 15% of all lung cancers and is strongly associated with 
smoking.1 SCLC is highly responsive to initial chemotherapy 
or radiotherapy. However, approximately 80% of the limited-
stage and nearly all extensive-stage patients develop recur-
rence. The patients who relapse after initial chemotherapy 
have a poor prognosis. The median survival is 2 to 3 months 
for the patients who do not receive salvage therapy.2 The 
results of second-line chemotherapy are also disappointing, 
with low response rates and short survival times.3
The efficacy of salvage chemotherapy depends on the 
response and the duration of the response to initial chemo-
therapy. The patients who recur more than 3 months after 
completion of the initial therapy are often termed as “sensitive 
relapse” patients. In contrast, the patients whose tumor does 
not respond or progress through treatment or who develop a 
recurrence within 3 months after completion of initial therapy 
are considered to be “refractory or resistant relapse” patients. 
Refractory patients have a dismal prognosis, with a survival of 
3 to 5 months and overall response rates (oRRs) of approxi-
mately 10% or less.4
Currently, topotecan is the only drug approved for sin-
gle-agent second-line SCLC treatment in the United States and 
is considered the standard second-line regimen in many coun-
tries. Topotecan showed an oRR of 24% and a median over-
all survival (oS) of 6 months in sensitive patients. However, 
topotecan seems to have only minimal activity in refractory 
disease, producing oRRs of 4 to 12% and an oS of 3.4 to 
5.8 months.4-6 In terms of toxicity, topotecan showed signifi-
cant adverse events, including grade-3 or -4 myelosuppression 
(neutropenia, 86–89%, thrombocytopenia, 43–57%, and ane-
mia 31–40%), diarrhea (6–8%), and fatigue (5–8%).4-8 More 
recently, amrubicin has shown favorable efficacy in relapsed 
SCLC patients (oRR, 17–60%, median survival, 5.3–12 
months) and is also currently in phase-III clinical evaluations.9 
12 Therefore, the development of new strategies for the man-
agement of this disease is urgently needed.
Belotecan (Camtobell, CKD602, 7-[-2(N-isopropy-
lamino)ethyl]-(20S)-camptothecin, Chong Keun Dang Corp., 
Seoul, Korea) is a new camptothecin analog, in which a 
water-solubilizing group is introduced at the position of the B 
ring.13 In the preclinical studies, belotecan was a more potent 
topoisomerase-I inhibitor and had superior antitumor activity 
compared to other camptothecin agents including topotecan. 
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Recently, several phase-II trials showed that belotecan was 
active and well tolerated as a single agent or in combination 
with cisplatin in untreated patients with SCLC.14 17 Two phase-
II trials of belotecan in second-line treatment of SCLC also 
showed modest efficacy and tolerable toxicity.18,19 However, 
these two studies had a small number of patients and had little 
data for refractory patients. one had only sensitive-relapsed 
patients (n = 27) and the other study (n = 25) had no infor-
mation on the type of relapse. Therefore, we evaluated the 
efficacy and toxicity of belotecan as a second-line chemother-
apy for a relatively large number of patients with relapsed or 
refractory SCLC.
PATIENTS AND METHODS
Data Source and Analytic Variables
Between June 2008 and August 2011, we identified 56 
patients who received belotecan monotherapy for refractory or 
relapsed SCLC at the Yonsei Cancer Center, Seoul, Korea. We 
excluded one patient who received the first-line chemotherapy 
after surgery and those who received a belotecan as third-line 
or later-line settings. Thus, 50 patients were left for analysis. 
We retrospectively collected and analyzed the data of these 
patients.
Patient characteristics were sex, age, performance sta-
tus, stage at diagnosis, initial chemotherapy regimen, the 
response of the initial chemotherapy, and the duration of 
the response to initial chemotherapy. A complete history of 
the treatment each patient had received for SCLC was 
recorded, including the start and stop dates of chemotherapy, 
dose of chemotherapy agents, reason for discontinuation, 
best response, and date of progressive disease (PD). The 
study was approved by the Institutional Review Board of the 
Severance Hospital.
Treatment
Belotecan was administered intravenously for more 
than 30 minutes once a day on days 1 to 5 for every 3 weeks. 
The dose of belotecan was 0.5 mg/m2/d during the first cycle, 
but a dose adjustment for the subsequent cycles was made 
according to the greatest degree of toxicity developed during 
the previous cycle. The dose was adjusted as follows: the dose 
would be decreased to 0.4 mg/m2/d in the event of (1) abso-
lute neutrophil count nadir of less than 500 /mm3 for 4 days 
or more (2) febrile neutropenia (3) platelet nadir of less than 
50,000 /mm3 for 4 days or more (4) thrombocytopenia asso-
ciated with bleeding episode or requiring transfusion or (5) 
grade-3 or higher nonhematological toxicity except alopecia, 
nausea, and vomiting. Dose increment was not allowed. The 
next cycle of treatment was started when absolute neutrophil 
count was 1500/mm3, platelet count was 100,000/mm3, and all 
nonhematologic toxicity except alopecia, nausea, and vomiting 
recovered to grade 2 or less. otherwise, the next cycle would 
be delayed for up to 3 weeks. Granulocyte colony-stimulating 
factor was used as a therapeutic intervention for neutropenia 
but not used as a prophylactic. Treatment was continued until 
one of the following events occurred: PD, termination of treat-
ment by the physician, and unacceptable toxicity which makes 
treatment interruption for more than 3 weeks.
Evaluation
All patients underwent a history-taking and physical 
examination, including documentation of concomitant medi-
cations, performance status, and history of smoking, labora-
tory tests (complete blood count, biochemistry profile, and 
urinalysis), and computed tomography scans of chest and 
abdomen electrocardiogram before the start of belotecan 
monotherapy. Tumor assessments were carried out once every 
two cycles. Toxicity was assessed twice every cycle (D+1 
and D+14). Tumor response was assessed by the Response 
Evaluation Criteria in Solid Tumors version 1.0.
Statistical Consideration
We analyzed the oRR, PFS, oS, and toxicity profiles. 
The distribution of baseline patient characteristics and a 
relapse pattern was evaluated by using Mantel-Haenszel 2 
tests for categorical variables and analysis of variance for con-
tinuous variables. We performed univariate and multivariate 
logistic regressions to evaluate the association between the 
patient characteristics and the efficacy. Survival curves were 
generated using the Kaplan Meier method and compared by 
the log rank test. Logistic regression and Cox’s proportional 
hazard model were used to determine the contribution of the 
clinico-pathological factors to response and survival, respec-
tively. All tests were two-sided, with a p-value of less than 0.05 
being considered statistically significant. The data were pre-
sented with 95% CIs and calculated using standard methods 
based on a binomial distribution. Data analysis was done by 
the SPSS software (version 18.0).
RESULTS
Patient Characteristics
From June 2008 to August 2011, a total of 50 patients 
were treated with belotecan monotherapy as a second-line 
treatment for relapsed or refractory SCLC. The baseline char-
acteristics of the patients are listed in Table 1. Four patients 
were women and 46 were men, and their median age was 66 
years (range, 43–84 years). Among the 50 patients, 34 (68%) 
had a PS of 0 or 1 before belotecan monotherapy. Sixteen 
patients (32%) had limited disease at diagnosis. Thirteen 
patients had received thoracic irradiation simultaneously with 
first-line chemotherapy. Twenty patients (40%) had sensitive 
relapse and 30 patients (60%) had refractory relapse. Almost 
all the patients (98%) had received etoposide-containing che-
motherapy and two patients had received an irinotecan-based 
regimen.
Treatment Delivery
Two patients died during the first cycle of treatment 
because of PD. Therefore, 48 patients received more than 
one cycle of treatment. In total, 130 cycles of treatment (68 
cycles for sensitive group and 62 cycles for refractory group) 
were administered, with a median of two cycles (range, one to 
nine cycles). The median duration of treatment was 6.5 weeks 
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(range, 3–31 weeks). Dose reduction and cycle delays of 
more than 7 days occurred in 6 patients (12%) and 15 patients 
(30%), respectively. The median relative dose intensity was 
0.92 (range, 0.4–1.0). Reasons for discontinuation of treatment 
were disease progression (n = 39), patient withdrawal (n = 2), 
unacceptable toxicity (n = 1), and others (n = 4). Among the 
43 patients who experienced disease progression after belo-
tecan chemotherapy, 12 (28%) received third-line salvage 
chemotherapy.
Efficacy
We were not able to evaluate the treatment response of 10 
patients because of death caused by early disease progression 
(7 patients), follow-up loss (1 patient), treatment-related tox-
icity (1 sepsis and 1 cerebral hemorrhage), and 2 patients were 
not yet evaluated. All these 12 patients were included in the 
efficacy analyses.
The oRR was 14% (95% CI, 4–24%). There was no 
complete response. The oRR of patients with sensitive relapse 
(20%; 95% CI, 8–40%) was higher than that of patients with 
refractory relapse (10%; 95% CI, 1–21%) (Table 2).
The median follow-up time is 4.2 months (range, 0.1–
19.2). At the time of analysis, 11 patients (22%) were alive. The 
median progression-free survival (PFS) and the oS were 1.6 
months (95% CI, 1.17–2.03) and 4.5 months (95% CI, 3.53–
5.47), respectively (Fig. 1). The oS of the patients with sensi-
tive relapse was significantly longer than that of the patients 
with refractory relapse (6.5 versus 4.0 months, p = 0.003, Fig. 
2A). The PFS of the patients with sensitive relapse had a trend 
toward a longer PFS than that of the patients with refractory 
relapse (2.8 versus 1.5 months, p = 0.053). The oS of the patients 
with good performance status (Eastern Cooperative oncology 
Group [ECoG] 0 or 1) was significantly longer than that of the 
patients with poor performance status (ECoG 2) (5.1 versus 
3.5 months, p = 0.045, Fig. 2B). In multivariate analysis, only 
the type of relapse was identified as an independent prognostic 
factor for PFS (hazard ratio [HR], 2.25; p = 0.035). The type 
of relapse (HR, 3.78; p = 0.003) and response to prior chemo-
therapy (HR, 0.285; p = 0.003) were identified as independent 
prognostic factors for oS (Appendix Table 1 , Supplemental 
Digital Content 1, http://links.lww.com/JTo/A256).
TABLE 1. Baseline Characteristics
Total  
(n = 50)
Sensitive Group  
(n = 20)
Refractory Group  
(n = 30)
Parameter No. of Patients % No. of Patients % No. of Patients % p-Value
Sex 0.67
 Male 46 92 18 90 28 93
 Female 4 8 2 10 2 7
Age, yrs 0.827
 Median 66 67 66
 Range 43–84 47–84 43–80
Performance status (ECoG) 0.677
 0 2 4 1 5 1 3
 1 32 64 14 70 18 60
 2 16 32 5 25 11 37
Stage at diagnosis 0.001
 Limited 16 32 12 60 8 13
 Extensive 34 68 4 40 26 87
Previous chemotherapy 0.012
 Etoposide + carboplatin 30 60 7 35 23 77
 Etoposide + cisplatin 18 36 12 60 6 20
 Irinotecan + carboplatin 2 2 1 5 1 3
Response to prior chemotherapy 0.83
 CR or PR 39 78 18 90 21 70
 SD or PD 11 22 2 10 9 30
ECoG, Eastern Cooperative oncology Group; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
TABLE 2. Response




Relapse (n = 30)
No. % No. % No. %
Complete 
response
0 0 0 0 0 0
Partial response 7 14 4 20 3 10
Stable disease 10 20 5 25 5 16.7
Progressive 
disease
21 42 7 35 14 46.7
Not evaluable 12 24 4 20 8 26.7
Response rate 7 14 4 20 3 10
95% CI 4–24% 8–40% 1–21%
CI, confidence interval.
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Toxicity
The toxicity profile is summarized in Table 3. The most 
common grade-3 to -4 hematologic toxicity was neutropenia 
that developed in 54% of the patients. Febrile neutropenia was 
observed in two patients. Grade-3 or -4 thrombocytopenia 
and anemia were developed in 38% and 32 % of the patients, 
respectively. The most frequent grade-3 or -4 nonhematologi-
cal toxicity was asthenia (6%). one patient died because of 
treatment-related toxicity, which was septic shock combined 
with pneumonia. Thrombocytopenia was the most frequent 
reason for dose reduction and neutropenia was the most com-
mon reason for cycle delay. Nonhematological toxicities were 
generally mild. There were no patients who had grade-3 to -4 
gastrointestinal toxicities.
DISCUSSION
We examined the efficacy and toxicity of belotecan, a 
new camptothecin analog, as a second-line treatment in a rela-
tively large number of relapsed or refractory SCLC patients. 
We observed modest antitumor activity of belotecan mono-
therapy in relapsed SCLC: an oRR of 14%, a median oS of 
4.5 months, and a median PFS of 1.6 months. The most com-
mon toxicity was myelosuppression (neutropenia 54%), and 
nonhematological toxicity was minimal.
Recently, Jeong et al18 reported that belotecan showed 
modest activity and manageable toxicities in sensitive-relapsed 
patients after first-line irinotecan chemotherapy (oRR, 22%; oS, 
13.1 months). Rhee et al19 also reported that belotecan induced 
an oRR of 24% and a median oS of 9.9 months. However, the 
Jeong et al had no refractory patients and Rhee et al had no 
information on the type of relapse. Thus, our study was the first 
report of belotecan as a second-line treatment for the refractory-
relapsed SCLC in a relatively large number of patients.
The type of relapse and performance status are well-
known prognostic factors for relapsed SCLC patients. In our 
study, the ratio of the refractory-relapsed patient was 60% and 
the patients with the poor performance status (ECoG = 2) was 
relatively higher than those of two recent phase-II trials (32 
versus 4–8%).18,19 The primary factor determining the likeli-
hood of response to second-line salvage therapy is whether 
the patient has refractory or sensitive relapse. In one report, 
the performance status was the second-most important predic-
tor of response to second-line salvage therapy.10 In this study, 
the oS of the patients with sensitive relapse was significantly 
longer than that of the patients with refractory relapse (6.5 
versus 4.0 months, p = 0.003). The oS of the patients with a 
Figure 1. Overall survival and progression-free survival. PFS, 
progression-free survival; OS, overall survival; CI, confidence 
interval.
Figure 2. Comparison of overall survival according to (A) 
the type of relapse and (B) the performance status.
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good performance status (ECoG 0 or 1) was also significantly 
longer than that of the patients with a poor performance status 
(5.1 versus 3.5 months, p = 0.045 Fig. 2).
Topotecan has been considered the standard second-line 
regimen in many countries. Recently, amrubicin has been consid-
ered as an alternative choice for relapsed SCLC patients, based 
on the recent trials of amrubicin that showed a favorable efficacy 
and toxicity.9-11 A randomized phase-II trial comparing amrubicin 
with topotecan in relapsed SCLC patients showed better response 
rates for both sensitive (53% versus 21%) and refractory (17% 
versus 0%) relapsed patients.12 A preliminary report of a phase-
III trial comparing amrubicin with topotecan as a second-line 
treatment for SCLC showed that amrubicin had significantly 
improved oRR and PFS compared to those of topotecan.20 We 
compared these two drugs with belotecan in second-line treat-
ment for relapsed SCLC (Table 4). According to the historical 
data review, the overall efficacy of belotecan was comparable to 
that of topotecan and slightly lower than that of amrubicin.
The major toxicity of belotecan was myelosuppression. 
Grade-3 or -4 hematological toxicities included neutropenia 
in 56.5% of the patients, thrombocytopenia in 40%, and ane-
mia in 35%. Previous studies have also demonstrated that the 
major toxicity of belotecan is myelosuppression. In phase-II 
studies of belotecan as second-line chemotherapy for relapsed 
SCLC patients, rates of grade-3 or -4 neutropenia, thrombo-
cytopenia, and anemia were 88 to 90%, 40 to 48%, and 29 to 
36% of the patients, respectively.18,19 In addition, in phase-II 
studies of belotecan monotherapy as a first-line treatment, 
grade-3 or -4 neutropenia, thrombocytopenia, and anemia 
developed in 70 to 74%, 13 to 30%, and 18 to 20% of the 
patients, respectively.14,17 The incidence of thrombocytopenia 
and anemia was consistent with that in previous studies.18,19 
However, the incidence of grade-3 or -4 neutropenia was rela-
tively lower than that in previous studies. This may be because 
of relatively high incidence of early progression. Fourteen 
patients (30%) had a PD after the first cycle of chemother-
apy. Nonhematological toxicities in our study were generally 
favorable to manage. This is consistent with the results of 
previous clinical trials.18,19 only two patients showed grade-3 
anorexia and none of the patients reported grade-3 or -4 gas-
trointestinal toxicities (nausea, vomiting, and diarrhea). This 
is favorable compared with that of grade-3 or -4 diarrhea for 
topotecan, ranging from 0.9 to 7.9% as a second-line trial.7,8 
Hematological toxicity of belotecan was comparable to that 
of topotecan and of amrubicin, and nonhematological toxicity 
of belotecan was milder than that of topotecan and amrubicin 
(Appendix Table 2, Supplemental Digital Content 1, http://
links.lww.com/JTo/A256).
Although several studies have shown belotecan to have 
a modest efficacy in patients with sensitive relapsed SCLC, 
there is a limitation of their adoption as standard treatment for 
relapsed SCLC, especially in refractory SCLC. This limitation 
might reflect that SCLC was the genetically complex human 
cancer. With regard to the complex biology of SCLC, the 
probability of developing a potent single novel drug against 
refractory SCLC was very low. Therefore, we should focus on 
identifying the driver mutations and the underlying mecha-
nism for rapid development of drug resistance for further 
TABLE 3. Toxicities (NCI-CTC Version 3.0)
CTC AE Terminology
All Grades Grade 3/4
No. % No. %
Hematological toxicity
 Neutropenia 38 76 27 54
 Anemia 47 94 16 32
 Thrombocytopenia 35 70 19 38
Nonhematological toxicity
 Asthenia 28 56 3 6
 Anorexia 11 22 2 4
 Nausea 17 34 0 0
 Vomiting 14 28 0 0
 Diarrhea 12 24 0 0
 Constipation 15 30 0 0
 Dyspnea 28 56 3 6
 Infection 13 26 3 6
 Liver enzyme elevation 14 28 0 0
NCI-CTC, National Cancer Institute-Common Toxicity Criteria; AE, adverse event.
TABLE 4. Comparison of Efficacy
Topotecan
BelotecanIntravenous Oral Amrubicin
Pawel8 Eckardt7 O’Brien5 Eckardt7 Inoue12 Onoda11 Kaira10 Ettinger9 Jeong18 Rhee19 Current Study
Type of relapse No data 10%* 57%* 9%* S R S R S R R only S only No data S R
Number of patients 107 151 70 153 17 12 44 16 10 19 75 27 25 20 30
Poor performance 
(%) (ECoG > 2)
23 12 27 13 13 1 3 5 17 4 8 25 37
Efficacy
 oRR (%) 24 18.3 7 21.9 53 17 52 50 60 37 21.3 22 24 20 10
 PFS (months) 3.3 3.0 4.1 3.8 3.9 2.6 4.2 2.6 4 4 3.2 4.7 2.2 2.8 1.5
 oS (months) 6.3 8.3 6.5 8.8 9.9 5.3 11.610.3 12 11 6 13.1 9.9 6.5 4
*The ratio of refractory-relapse patients.
S, sensitive relapse; R, resistance-relapse or refractory patients; ECoG, Eastern Cooperative oncology Group; oRR, overall response rate; PFS, progression-free survival; oS, 
overall survival.
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clinical trials of second-line treatment in patients with refrac-
tory SCLC. Advanced technology such as next-generation 
sequencing should be introduced to identify such key genetic 
events. Based on gene-expression profiling and toxicity of 
drugs, we should select a proper combination of regimens for 
further investigations of refractory SCLC.
The main limitation of the present study resides in its 
retrospective nature. Another limitation is the relatively high 
incidence of early progression in our study, mainly because 
of inclusion of a large number of refractory SCLC patients 
with poor performance status. Furthermore, the toxicity of 
the belotecan might not be adequately reflected in this study 
because of early progression in many patients. Thus, we are 
currently conducting a randomized phase-II study comparing 
belotecan with topotecan. It will reveal more precise informa-
tion about the efficacy and toxicity of belotecan in relapsed or 
refractory SCLC.
In conclusion, belotecan showed modest activity and 
manageable toxicity as a second-line treatment in patients 
with relapsed or refractory SCLC. Considering the limited 
activity of belotecan for refractory relapsed patients, an effort 
has to be made to find key genetic events for further studies of 
belotecan in refractory SCLC.
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